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AbstractThis is the ﬁrst report of Actinomyces europaeus bacteraemia in a 53-
year-old man. The bacteraemia was the result of a breast abscess.
Identiﬁcation was established by matrix-assisted desorption
ionization–time of ﬂight mass spectrometry and conﬁrmed by
16S rRNA gene sequencing. The patient was treated with surgical
drainage and penicillin for 4 weeks; the patient did not experience
any relapse during 6 months of follow-up.
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E-mail: halin@rn.dkActinomyces species are part of the commensal ﬂora of the
mucous membranes of the oropharynx, gastrointestinal tract
and female genital tract. Many Actinomyces species are oppor-
tunistic pathogens of humans that may lead to actinomycosis, a
slowly processing indolent granulomatous infection, often
located in the cervicofacial, thoracic, abdominal and in women
also the pelvic areas [1]. Breast infection with Actinomyces spe-
cies is an unusual condition. Nevertheless, A. israelii, A. turicensis,
A. radingae, A. viscosus, A. meyerii, A. neuii and A. europaeus have all
been associated with breast infection in women [2–7]. Breast
infection in men with Actinomyces species is rare. Only a single
case of a 73-year-old man with a primary breast abscess from
A. neuii mimicking an epidermoid cyst has been reported [8].New Microbes and New Infections © 2015 The Author. Published by El
This is an open access artiActinomyces europaeus is a short, nonmotile, facultative
anaerobic rod ﬁrst described in 1997 [9]. Besides breast ab-
scesses, A. europaeus has been described in urinary tract in-
fections as well as skin and soft tissue infections [10]. To my
knowledge, the present case is the ﬁrst report of A. europaeus
bacteraemia resulting from a breast abscess.
A 53-year-old Danish man was hospitalized in July 2014 with a
painful swelling in the right breast which had appeared a few days
earlier. The patient was diabetic and smoking 20 to 30 cigarettes
a day. He had a history of obesity, chronic obstructive pulmo-
nary disease and schizophrenia. Previously he had been experi-
enced recurrent cutaneous abscesses, primarily localized to the
axillae and the groin, which were treated with surgical drainage.
At examination, the patient was febrile (39.5°C) and had
tachycardia and tachypnea. His right breast was diffusely
swollen, and there was a hyperaemic area of 10 × 30 cm. He
was also severely obese, with a body mass index of 45.9 kg/m2,
and laboratory test showed a C-reactive protein level of
275 mg/L and white blood cell count of 14.3 × 109/L. A chest X-
ray revealed nothing abnormal. A blood culture was performed,
and thereafter antimicrobial therapy was initiated with intra-
venous dicloxacillin 1 g three times a day. By ultrasound, a large
abscess formation in the right breast was visualized, including a
sinus tract located in the right inframammary region. Through
the sinus, a pigtail catheter was inserted into the abscess, and
there was a prompt discharge of thick pus. After drainage, the
patient quickly improved; he was discharged on day 2 with oral
ﬂucloxacillin 1 g three times a day. Nevertheless, on day 5, the
patient was rehospitalized as a result of increased purulent
secretion from the sinus, and the antimicrobial therapy was
changed to intravenous cefuroxime 1.5 g three times a day.
From the blood culture system (BacT/Alert 3D; BioMérieux,
Marcy l’Etoile, France), the standard anaerobic bottle had a
positive growth of short, nonmotile, Gram-positive coccoid
rods after 5 days of incubation. The isolate were negative for
catalase, urease and nitrate reduction but showed a positive
fermentation of maltose. The coccoid rods was identiﬁed as
A. europaeus by matrix-assisted laser desorption– ionization
time of ﬂight mass spectrometry (MALDI-TOF MS; Vitek MS;
BioMérieux) with 99.9% probability as well as partial sequencing
of the 16S rRNA gene (ABI Prism Big Dye Sequencing kit)
(GenBank accession KP752177). BLAST analysis showed 99%
identity with the 16S rRNA gene sequence of A. europaeus
strain CCUG 32789A (GenBank accession NR_114971). The
A. europaeus was susceptible to all antimicrobial agents tested
according to the Clinical and Laboratory Standards Institute
criteria by Etest (BioMérieux) with the following minimum
inhibitory concentration results: penicillin G, 0.064 mg/L;
piperacillin–tazobactam, 0.125 mg/L; ceftriaxone, 0.125 mg/L;New Microbe and New Infect 2015; 7: 21–22
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mycin, 0.032 mg/L; and moxiﬂoxacin, 0.250 mg/L.
Gram staining of the pus revealed a high number of short
Gram-positive coccoid rods, but no sulphur granules were seen.
Cultures grew A. europaeus and Porphyromonas species. The Por-
phyromonas species was susceptible to penicillin and metronida-
zole andwas not further characterized. TheA. europaeus frompus
also was susceptible to all antimicrobial agents tested as above.
On day 8, the antimicrobial therapy was changed to oral
penicillin 1.2 million units four times a day for 4 weeks. Finally,
the patient was discharged on day 11 with a clean abscess cavity
of 4 × 5 cm with no purulent secretion, and the breast
remained painless. After 6 months, the patient had not been
rehospitalized with recurrent infection in the breast.
To my knowledge, this is the ﬁrst report of A. europaeus
bacteraemia. The A. europaeus was isolated from both blood
and the abscess cavity, and therefore it is fair to conclude that it
was the main causal agent, whereas the Porphyromonas species
was of minor importance. The patient had several comorbid-
ities like diabetes, obesity, chronic obstructive pulmonary dis-
ease and schizophrenia. Previously he had experienced
recurrent skin infections and cutaneous abscesses, and there-
fore it is plausible that A. europaeus reached the mammary
tissue through skin lacerations with dissemination to the
bloodstream. However, as a function of the increased usage of
MALDI-TOF MS, the term “ﬁrst report” may have a potential
limitation because there may be an opportunity for previous
cases of bacteraemia with A. europaeus encountered and re-
ported with the simple identiﬁcation as Actinomyces species.
The traditional treatment for actinomycosis is high-dose
penicillin for prolonged period of 6 to 12 months. However,
shorter treatment regimens have been successful [11]. To my
knowledge, all cases of breast infection with Actinomyces species
have been successfully treated with a combination of surgical
drainage and antibiotic therapy. Minimum inhibitory concen-
trations for all antibiotics tested against were all very low, but
other strains of A. europaeus have shown reduced susceptibility
to piperacillin–tazobactam, ciproﬂoxacin, clindamycin and
erythromycin [12]. The patient was treated with intravenous
β-lactam antibiotics for 1 and 4 days, separated by 3 days of oral
ﬂucloxacillin. Finally, he was treated with 4 weeks of oral
penicillin. Overall, this treatment seems short compared to the
traditional recommendation for actinomycosis, but the patient
did not have any relapse during the 6 months of follow-up.
This report conﬁrms the pathogenic potential of A. europaeus,
but future studies are needed to elucidate the clinical signiﬁcance
of this bacterium. Furthermore, future studies are needed to
conﬁrm that antibiotic treatment can be individualized and
short-term regimens of only 4 weeks may be sufﬁcient.New Microbes and New Infections © 2015 The Author. Published by Elsevier Ltd on behalf of
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